Medical Affairs Office, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
J Orthop Surg Res. 2023 May 24;18(1):381. doi: 10.1186/s13018-023-03855-w.
Omega-3 polyunsaturated fatty acids (n-3 PUFAs) confers anti-inflammatory efficacy, which has been suggested to be effective for patients with osteoarthritis (OA). However, previous studies evaluating the influence of n-3 PUFAs supplementation in patients with OA showed inconsistent results. We performed a systematic review and meta-analysis to comprehensively evaluate the influence of n-3 PUFAs on symptom and joint function of patients with OA.
Relevant randomized controlled trials (RCTs) were obtained by searching PubMed, Embase, and Cochrane Library databases. A random-effects model was employed to combine the results.
Nine RCTs with 2070 patients with OA contributed to the meta-analysis. Pooled results showed that n-3 PUFAs supplementation could significantly relieve the arthritis pain as compared to placebo (standardized mean difference [SMD]: - 0.29, 95% confidence interval [CI] - 0.47 to - 0.11, p = 0.002, I = 60%). Besides, supplementation with n-3 PUFAs was also associated with improved joint function (SMD: - 0.21, 95% CI - 0.34 to - 0.07, p = 0.002, I = 27%). Subgroup analysis showed consistent results of studies with arthritis pain and joint function evaluated by the Western Ontario-McMaster University Osteoarthritis Index and other scales (p for subgroup difference = 0.33 and 0.34, respectively). No severe treatment-related adverse events (AEs) were observed in the included patients, and the incidence of overall AEs was similar between groups (odds ratio: 0.97, 95% CI 0.64-1.45, p = 0.86, I = 0%).
Supplementation of n-3 PUFAs is effective to relieve pain and improve joint function in patients with OA.
ω-3 多不饱和脂肪酸(n-3 PUFA)具有抗炎作用,已被证明对骨关节炎(OA)患者有效。然而,先前评估 n-3 PUFA 补充对 OA 患者影响的研究结果不一致。我们进行了系统评价和荟萃分析,以全面评估 n-3 PUFA 对 OA 患者症状和关节功能的影响。
通过检索 PubMed、Embase 和 Cochrane Library 数据库获得相关随机对照试验(RCT)。采用随机效应模型对结果进行合并。
9 项 RCT 共纳入 2070 例 OA 患者,纳入荟萃分析。汇总结果显示,与安慰剂相比,n-3 PUFA 补充剂能显著缓解关节炎疼痛(标准化均数差 [SMD]:-0.29,95%置信区间 [CI]:-0.47 至 -0.11,p=0.002,I²=60%)。此外,n-3 PUFA 补充剂还与改善关节功能相关(SMD:-0.21,95%CI:-0.34 至 -0.07,p=0.002,I²=27%)。亚组分析显示,采用 Western Ontario-McMaster 大学骨关节炎指数和其他量表评估关节炎疼痛和关节功能的研究结果一致(p 亚组差异=0.33 和 0.34)。纳入患者中未观察到严重的治疗相关不良事件(AE),且组间总体 AE 发生率相似(比值比:0.97,95%CI:0.64-1.45,p=0.86,I²=0%)。
n-3 PUFA 补充剂可有效缓解 OA 患者的疼痛并改善关节功能。